Jules Haimovitz Net Worth

Jules Haimovitz biography

Jules A. Haimovitz serves as Independent Director of the Company. He has served as a member of our Board of Directors since February 2018 and is currently a member of the Audit Committee and the Compensation Committee. Mr. Haimovitz is currently President of Haimovitz Consulting, Inc. He previously served as a member of the board of directors of Ariad Pharmaceuticals, where he was also a member of its audit committee; Dial Global, Inc., where he was also member of its audit committee; and Imclone Pharmaceuticals, where he served as chairperson of its audit committee. Mr. Haimovitz has also served as Chief Executive Officer or Chief Operating Officer of the following companies: Spelling Entertainment, Inc., King World Productions and VJN, Inc. Mr. Haimovitz holds a B.S. and M.A. degree in Mathematics from Brooklyn College. Mr. Haimovitz has demonstrated leadership in his field, his knowledge of financial and financing matters and his prior board service contributed to our conclusion that he should serve as a director.

What is the salary of Jules Haimovitz?

As the Independent Director of Innoviva Inc, the total compensation of Jules Haimovitz at Innoviva Inc is $322,494. There are 4 executives at Innoviva Inc getting paid more, with Marianne Zhen having the highest compensation of $551,918.

How old is Jules Haimovitz?

Jules Haimovitz is 69, he's been the Independent Director of Innoviva Inc since 2018. There are no older and 7 younger executives at Innoviva Inc.

What's Jules Haimovitz's mailing address?

Jules's mailing address filed with the SEC is 5005, McConnell Avenue, Del Rey, Los Angeles, Los Angeles County, California, 90066, United States.

Insiders trading at Innoviva Inc

Over the last 9 years, insiders at Innoviva Inc have traded over $394,127,811 worth of Innoviva Inc stock and bought 682,000 units worth $8,768,520 . The most active insiders traders include Plc Gsk, Alexander J Sarissa Capital..., ePatrick G Lepore. On average, Innoviva Inc executives and independent directors trade stock every 78 days with the average trade being worth of $18,199,955. The most recent stock trade was executed by Marianne Zhen on 15 November 2023, trading 10,994 units of INVA stock currently worth $153,806.

What does Innoviva Inc do?

innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.

Innoviva Inc executives and stock owners

Innoviva Inc executives and other stock owners filed with the SEC include:

• Marianne Zhen,
  Chief Accounting Officer
• Marianne Zhen CPA,
  Chief Accounting Officer
• Pavel Raifeld C.F.A.,
  Chief Exec. Officer
• George Bickerstaff,
  Independent Director
• Jules Haimovitz,
  Independent Director
• Odysseas Kostas,
  Independent Chairman of the Board
• Sarah Schlesinger,
  Independent Director
• Mark DiPaolo,
  Independent Director
• Pavel Raifeld,
  Chief Executive Officer
• Paul Pepe,
  Director
• Michael W Aguiar,
  President & Chief Exec Officer
• Barbara Gayle Duncan,
  Director
• William H Waltrip,
  Director
• Theodore L Jr Witek,
  Sr. VP & Chief Scientific Off.
• Cathy Friedman,
  Director
• James L Tyree,
  Director
• Michael E. Faerm,
  Sr VP & Chief Business Officer
• George B Abercrombie,
  Sr. VP & Chief Comm. Officer
• Patrick G Lepore,
  Director
• Eric D Esparbes,
  SVP and CFO
• Alexander J Sarissa Capital...,
  
• Matthew Ronsheim,
  See Remarks
• Geoffrey Hulme,
  Interim Principal Exec Officer
• Deborah Birx,
  Director
• Plc Gsk,
  10% owner
• Derek A Small,
  Director
• Sapna Srivastava,
  Director
• Margaret Koziel,
  Chief Medical Officer
• Stephen Basso,
  Chief Financial Officer